CLINICAL CANCER OF THE
Melanoma is the fastest growing and fifth most common cancer. The standard for diagnosing and staging melanoma is a biopsy of the primary tumor followed by surgical removal and histological assessment of the sentinel lymph nodes (SLNs). Detection of SLNs is performed via lymphoscintigraphy, following injection of the radioactive compound Technetium (99mTc). The diagnostic work-up is therefore highly invasive and exposes the patient to ionizing radiation. Initial clinical trials show that MSOT has the potential to be a non-invasive and radiation-free alternative for primary lesion characterization, SLN detection, and assessment of metastatic involvement of SLNs.